Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|2|188-198

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.2, 2015-04, pp. : 188-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

By  

Acta Haematologica, Vol. 136, Iss. 2, 2016-05 ,pp. : 76-84

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 7-14

Karger

Access to resources Recommend Favorite

R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 4, 2018-02 ,pp. : 534-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 22-27

Karger

Access to resources Recommend Favorite

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 352-355

John Wiley & Sons Inc

Access to resources Recommend Favorite